283 related articles for article (PubMed ID: 2647312)
21. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
22. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of carboplatin after intraperitoneal administration.
Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG
Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734
[TBL] [Abstract][Full Text] [Related]
24. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
25. [Platinum derivatives].
Sasaki Y
Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
[No Abstract] [Full Text] [Related]
26. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG
Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665
[TBL] [Abstract][Full Text] [Related]
29. The disposition of carboplatin in the beagle dog.
Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH
Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707
[TBL] [Abstract][Full Text] [Related]
30. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
34. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
37. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
39. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
Fujiwara K; Miyagi Y; Hayase R; Yoshinouchi M; Kobashi Y; Kohno I; Sekiba K
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1943-8. PubMed ID: 3289504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
